Product Description
NEO 212 is novel DNA alkylating agent exhibiting superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo. NEO212 is a conjugate of temozolomide (TMZ,) with the natural product perillyl alcohol (POH). NEO 212 causes DNA damage and cell death much more efficiently than TMZ because linkage with POH increased it's biological half-life and thus provided greater opportunity for placement of cytotoxic DNA lesions. (Sourced from: https://drugs.ncats.io/drug/237TB781D9)
Mechanisms of Action: Alkylating agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neonc Technologies
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma|Astrocytoma|Brain Stem Cancer|Carcinoma, Merkel Cell|Central Nervous System Cancer|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Glioblastoma|Head and Neck Cancer|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Uterine Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06047379 |
NEO212-01 | P2 |
Recruiting |
Gastrointestinal Cancer|Melanoma|Glioblastoma|Head and Neck Cancer|Transitional Cell Carcinoma|Carcinoma, Merkel Cell|Squamous Cell Carcinoma|Colorectal Cancer|Esophageal Cancer|Adenocarcinoma|Brain Stem Cancer|Renal Cell Carcinoma|Central Nervous System Cancer|Astrocytoma|Cervical Cancer|Non-Small-Cell Lung Cancer|Uterine Cancer |
2027-02-28 |
12% |
2025-12-20 |
Primary Endpoints |